Adam Jacob Schoenfeld MD

PubMed

• Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
  Rodabe N Amaria, Krishna V Komanduri, Adam J Schoenfeld, Giridharan Ramsingh, Rachel A Burga
  Cytotherapy. 2025-07-01
• Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell ...
  Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, Biagio Ricciuti, Joao V Alessi
  Clinical Cancer Research. 2025-06-13
• LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-PD-(L)1 Plus Platinum Chemotherapy.
  Natasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, Rina Hui, Sofia Baka
  Journal of Thoracic Oncology. 2025-06-03

Journal Articles

• Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  
  Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
• Synthesis, Structure, Dynamics, and Selective Methylation of Platinum and Palladium Diphosphametallacyclobutane Complexes  
  Chapp TW, Schoenfeld A, Sanderson MD, Chang C, Glueck DS, Golen J, Moore C, Rheingold A, Organometallics, 2012
• Effects of Linker Length on the Rate and Selectivity of Platinum-Catalyzed Asymmetric Alkylation of the Bis(isitylphosphino)alkanes IsHP(CH2)nPHIs (is = 2,4,6-(i-pr)3C...  
  Chapp TW, Schoenfeld A, Glueck DS, Organometallics, 2010

Abstracts/Posters

• The CNS Germinoma Experience at UCSF from 1980 to 2010
  Schoenfeld A, Molinaro A, Banerjee A, Haas-Kogan D, Mueller S, 3rd International CNS Germ Cell Tumour Symposium, Cambridge, England, 2013

Lectures

• Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers. 
  2019 ASCO Annual Meeting - 6/1/2019